



InterQual® Behavioral Health Services Criteria

InterQual® 2024 March Release Clinical Revisions

Release date: March 22, 2024

Revisions sections

The following sections describe the criteria revisions for this release.

[New subsets](#)

[Revisions to criteria](#)

[Revisions to medical codes](#)

New subsets

- None

Revisions to criteria



Revision Summary

Applied Behavior Analysis (ABA) Program: Disclaimer added to recommendations to clarify intent of numeric values.

Electroconvulsive Therapy (ECT): Literature was reviewed, and citations and notes updated. Disclaimer added to recommendations to clarify intent of numeric values. Criteria change shown below.

Neuropsychological and Developmental Testing: Disclaimer added to recommendations to clarify intent of numeric values.

Pharmacogenomic Testing for Psychotropic Medication Drug Response: Literature was reviewed, and citations and notes updated.

For individuals who are receiving antidepressant therapy or obsessive-compulsive disorder (OCD) therapy and are candidates for the selective serotonin reuptake inhibitor (SSRI) sertraline, genetic testing for CYP450 CYP2B6 was added. If the individual is a candidate for initial antidepressant medication, genotyping for CYP2B6 has limited evidence and may be tested with or without CYP450 CYP2C19. In individuals that have received previous medications that had limited or inadequate improvement or adverse drug reactions and are being prescribed Sertraline, CYP2B6 testing is recommended with or without CYP450 CYP2C19 or a pharmacogenomic panel test.

Psychological Testing: Disclaimer added to recommendations to clarify intent of numeric values.

Transcranial Magnetic Stimulation (TMS): Literature was reviewed, and citations and notes updated. Disclaimer added to recommendations to clarify intent of numeric values. Criteria change shown below.

Urine Drug Testing (UDT): Literature was reviewed, benchmarks, citations and notes updated. Disclaimer added to recommendations to clarify intent of numeric values.

Electroconvulsive Therapy (ECT)		
Component	Revision	Rationale
Question	Changed “Unipolar depression and trials of ≥ 2 different antidepressants from ≥ 2 different classes and at adequate doses and duration or stopped due to intolerable adverse effects” to “Unipolar depression and trials of ≥ 2 different antidepressants at adequate doses and duration or stopped due to intolerable adverse effects”	Although it is common practice to switch antidepressant class when one antidepressant, at adequate dose and duration, is determined ineffective, the most accepted definition of treatment-resistant depression (TRD) is failure to remit after two or more antidepressant treatment trials.
Transcranial Magnetic Stimulation (TMS)		
Component	Revision	Rationale
Question	Changed “Trials of at least 4 different antidepressants from at least 2 different pharmacological classes” AND “Trials of at least 3 different antidepressants from at least 2 different pharmacological classes and augmenting agent added to at least 1 trial” to “Trials of at least 2 different antidepressants.”	There is variation on how treatment-resistant depression (TRD) is defined in the literature, but the most accepted definition is failure to remit after two or more antidepressant treatment trials. Furthermore, TMS studies demonstrating antidepressant efficacy often use subjects who failed two antidepressant trials.
Question	Removed “Stroke and improving functioning”	Additional development work needed for this condition
Pharmacogenomic Testing for Psychotropic Medication Drug Response		
Component	Revision	Rationale
Attention-deficit/hyperactivity disorder (ADHD) therapy Recommendation	Changed Current evidence does not support testing in this clinical scenario to CYP450 CYP2D6 genotyping for psychotropic medications (Limited Evidence, additional review required) When Medications include Atomoxetine	CYP450 CYP2D6 metabolizer status may impact effectiveness of atomoxetine metabolism and dosage adjustments may be necessary. Genotyping prior to treatment can be considered on an individual basis.

Revisions to medical codes

Subset Description (Guideline Name)	Test Code Description (Recommendation)	CPT/HCPCs	Revision
Pharmacogenomic Testing for Psychotropic Medication Drug Response	CYP450 CYP2B6 genotyping for psychotropic medications	81479	Add

Review and Incorporation of Recent Medical Literature

Optum, Inc. is committed to keeping the InterQual product suite current and accurate. Criteria are continually reviewed and updated, with new editions of every product released at least annually. Optum's staff of physicians, nurses, other licensed healthcare professionals, and its extensive array of primary care and specialty consultants participate in ongoing criteria revision as new medical information emerges. Each release of the criteria reflects a thorough review of new medical literature, society guidelines, current practice standards, and incorporation of expert clinical consultant and user feedback.

Additional Resources

InterQual® Resource Center

The [InterQual Resource Center](#) is a central location for the most up-to-date InterQual clinical documentation and resources.

The Resource Center provides access to:

- What's New—Includes release highlights for each of the InterQual® Criteria modules included in a content release.
- Clinical Revisions—Includes the clinical revisions for the current InterQual Criteria year and two years prior.
- Clinical Resources—Includes information such as the Knowledge Articles, the Known Issues List, and more.
- Webinars—Includes the Increase Your IQ educational webinar recordings.
- Additional Resources—Includes access to resources such as Customer Care Hub, the InterQual® Learning Source, and Download Connect.

Accessing Customer Care Hub

[Customer Care Hub](#) is a web portal that enables you to submit, update, and view support case details and status.

To obtain a user ID and password, from the Customer Care Hub Welcome page, select Request Account.

Proprietary Notice

General Terms:

Optum Inc., and/or one of its subsidiaries (“**Optum**”) is the owner/licensor of InterQual® Criteria Modules (the “**Clinical Content**” or the “**Work**”). Optum has prepared this Work for exclusive use of its licensees of software applications embodying the Clinical Content. This Work contains confidential and trade secret information of Optum and is provided to licensees who have an existing license agreement in force only under the time-limited license as provided under that license agreement. Licensee and any recipient shall use the Work in accordance with the terms and conditions of the license agreement.

Proprietary Notice:

The Work is protected under United States and international copyright and other intellectual property laws. If this Work is delivered pursuant to a federal government contract that requires the conveyance of rights in data to the government, it is understood that the Work, including commercial software, clinical content, third-party software, documentation and/or other technical data, was developed exclusively at Optum's private expense, and that Optum will convey only limited or restricted rights in the Work to the government consistent with the guidance set forth in the Federal Acquisition Regulation (“FAR”) and/or FAR Supplements. Conveyance of any additional rights beyond limited or restricted rights in the Work requires Optum's express consent contained in a separate written agreement.

© 2013-2024 Optum, Inc. and/or one of its subsidiaries. All rights reserved.

Acknowledgments and Disclaimer:

The Clinical Content is developed by Optum's clinical research staff which includes physicians, registered nurses, and other healthcare professionals. Many of Optum's clinical staff hold advanced degrees and case management certification. The Clinical Content is reviewed and validated by a national panel of clinicians and medical experts, including those in community and academic practice settings, as well as within the managed care industry throughout the United States. The Clinical Content is a synthesis of evidence-based standards of care, current practices, and consensus from licensed specialists and/or primary care physicians.

The Clinical Content reflects clinical interpretations and analyses and cannot alone either resolve medical ambiguities of particular situations or provide the sole basis for definitive decisions. The Clinical Content is intended solely for use as screening guidelines with respect to the medical appropriateness of healthcare services and not for final clinical or payment determinations concerning the type or level of medical care provided, or proposed to be provided, to a patient.

THE WORK IS PROVIDED “AS IS.” OPTUM DISCLAIMS ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING AS TO MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR SERVICE OF THE WORK, OR THE COMPATIBILITY OF OUTPUT USING THE WORK WITH ANY LAW, REGULATION, OR ORDER. IN NO EVENT SHALL OPTUM BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES IN CONNECTION WITH, OR ARISING OUT OF, ANY USE OF THE WORK.

Trademarks:

InterQual® is a trademark of Optum, Inc. and/or one of its subsidiaries. All other trademarks are the property of their respective owners.

Third Party Notices:

AMA CPT® Codes: The Work may incorporate the CPT® terminology developed and copyrighted by the American Medical Association (“AMA”). The CPT codes and terminology are provided pursuant to a license agreement between Optum (or one of its affiliates) and the AMA.

CPT copyright 2012-2023 American Medical Association. All rights reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

Applicable FARS/DFARS Restrictions Apply to Government Use.

U.S. Government Rights

CPT is commercial technical data, which was developed exclusively at private expense by the American Medical Association (AMA), 330 North Wabash Avenue, Chicago, Illinois, 60611. The Federal Government is not granted a direct license to CPT based on FAR 52.227-14 (Data Rights-General) and DFARS 252.227-7015 (Technical Data – Commercial Items). Government End Users may receive the same commercial license granted to Optum’s, or Optum affiliates’, other End Users.

BCBSA MPRM: The BCBSA Medical Policy Reference Manual (MPRM) is the proprietary and confidential information of Blue Cross Blue Shield Association. © 2001-2024 Blue Cross Blue Shield Association. All Rights Reserved. The MPRM content is licensed to Optum, Inc. and/or one of its subsidiaries.

NCCN Compendium: © National Comprehensive Cancer Network, Inc 2011-2024, All Rights Reserved. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, NCCN TEMPLATES®, and NCCN COMPENDIUM® are trademarks owned by the National Comprehensive Cancer Network, Inc.

ASAM Criteria: The ASAM Criteria, Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions, Third Edition. Copyright © 2013-2024 American Society of Addiction Medicine (ASAM).

ASAM Criteria: The ASAM Criteria, Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions, Fourth Edition. Copyright © 2023-2024 American Society of Addiction Medicine (ASAM).

Concert Genetics: Concert Genetics, Concert GTU, and GTU are registered trademarks of Concert Genetics, Inc. All content in the Concert Genetics® Navigator is the property of Concert Genetics, Inc. © 2024 Concert Genetics, Inc. All rights reserved.

CDC HRQOL-14: Health-related quality of life survey, also known as the CDC HRQOL-14 or "Healthy Days Measures", is available in the public domain from the Centers for Disease Control and Prevention.

Edinburgh Postnatal depression scale: Cox, J.L., Holden, J.M., and Sagovsky, R. 1987. Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry 150:782-786 .K. L. Wisner, B. L. Parry, C. M. Piontek, Postpartum Depression N Engl J Med vol. 347, No 3, July 18, 2002, 194-199

Katz Index of Independence in Activities of Daily Living Scale: Katz, S., Downs, T. D., Cash, H. R., & Grotz, R. C. (1970). "Progress in Development of the Index of ADL." *The Gerontologist*, Vol. 10 (1 Part 1), 20-30. Reproduced with permission.

Lawton Brody Instrumental Activities of Daily Living Scale: Lawton, M. P. & Brody, E. M. (1969). "Assessment of Older People: Self-maintaining and Instrumental Activities of Daily Living." *The Gerontologist*, Vol. 9 (3 Part 1), 179-186. Reproduced with permission.

MAHC-10 Tool: The Multi-Factorial Fall Risk Assessment Tool (MAHC-10) developed by the Missouri Alliance for Home Care (MAHC). Reproduced with permission.

Patient Health Questionnaire: Patient Health Questionnaire (PHQ-2 and PHQ-9) developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. Reproduced with permission.

Six-Item Screener: Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, Hendrie HC. (2002). Six-item screener to identify cognitive impairment among potential subjects for clinical research. *Medical Care*, 40(9), 771-781. Reproduced with permission.

Two Item Conjoint Screen (TICS): Brown, R. L., Leonard, T., Saunders, L. A. & Pappasoulotis, O. (2001). A two-item conjoint screen for alcohol and other drug problems. *J Am Board Fam Pract*, 14, 95-106. Reproduced with permission.

Generalized Anxiety Disorder Screen (GAD-7): "A brief measure for assessing generalized anxiety disorder: the GAD-7". Spitzer RL, Kroenke K, Williams JB, Löwe B. *Arch Intern Med*. 2006 May 22; 166(10):1092-7. Doi:10.1001/archinte/166/10/1092. PMID: 16717171. Reproduced with permission.

Third Party Calculators:

This Work includes links to the third party calculators ("calculators") listed in the table below. These calculators are developed by third parties, not Optum. Optum provides the links to the sites that control these calculators solely as a convenience. Optum has no control over and shall not be responsible for and assumes no liability for the calculations produced by the calculators. For additional information on the calculators, contact the third parties in the table below.

Third Party	Link to Calculator
Merck Manual - MD Calc	https://www.merckmanuals.com/medical-calculators/CommunityAcqPneumonia-ja.htm
Social Security Actuarial Life Table (I)	https://www.ssa.gov/oact/STATS/table4c6.html
Fracture Risk Assessment Tool (FRAX)	https://www.sheffield.ac.uk/TBS/
Breast Cancer Risk Assessment Tool	https://bcrisktool.cancer.gov/
BRCAPRO	https://projects.iq.harvard.edu/bayesmendel/brcapro

Third Party	Link to Calculator
CanRisk (BOADICEA)	https://canrisk.org/about/
UNC	https://www.med.unc.edu/mfm/nips-calc
Marfan Foundation	http://www.marfan.org/dx/zscore
Marfan Foundation	https://marfan.org/dx/score/
